SG11202005983TA - Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors - Google Patents
Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitorsInfo
- Publication number
- SG11202005983TA SG11202005983TA SG11202005983TA SG11202005983TA SG11202005983TA SG 11202005983T A SG11202005983T A SG 11202005983TA SG 11202005983T A SG11202005983T A SG 11202005983TA SG 11202005983T A SG11202005983T A SG 11202005983TA SG 11202005983T A SG11202005983T A SG 11202005983TA
- Authority
- SG
- Singapore
- Prior art keywords
- mertk
- tyro3
- axl
- tam
- family
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762610994P | 2017-12-28 | 2017-12-28 | |
PCT/US2018/067532 WO2019133629A1 (en) | 2017-12-28 | 2018-12-26 | Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202005983TA true SG11202005983TA (en) | 2020-07-29 |
Family
ID=67068139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202005983TA SG11202005983TA (en) | 2017-12-28 | 2018-12-26 | Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors |
Country Status (10)
Country | Link |
---|---|
US (1) | US11407757B2 (en) |
EP (1) | EP3731845A4 (en) |
JP (1) | JP2021510729A (en) |
KR (1) | KR20200104336A (en) |
CN (1) | CN112203659A (en) |
AU (1) | AU2018397483A1 (en) |
CA (1) | CA3086714A1 (en) |
SG (1) | SG11202005983TA (en) |
TW (1) | TWI691500B (en) |
WO (1) | WO2019133629A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023043836A1 (en) * | 2021-09-15 | 2023-03-23 | Metacrine, Inc. | Hsd17b13 inhibitors and uses thereof |
WO2023049270A1 (en) * | 2021-09-24 | 2023-03-30 | Halia Therapeutics, Inc. | Pyrrole[2,3-b]pyridine derivatives as tyro3 inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006301435A1 (en) * | 2005-10-13 | 2007-04-19 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as Syk inhibitors |
EP2188292B1 (en) * | 2007-08-08 | 2013-05-29 | GlaxoSmithKline Intellectual Property Development Limited | 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d]pyrimidin-4-yl) amino]benzamide derivatives as igf-1r inhibitors for the treatment of cancer |
WO2009049028A1 (en) * | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
CN102307875A (en) * | 2009-02-09 | 2012-01-04 | 苏伯俭股份有限公司 | Pyrrolopyrimidinyl axl kinase inhibitors |
CA2850617A1 (en) * | 2011-10-03 | 2013-04-11 | The University Of North Carolina At Chapel Hill | Pyrrolopyrimidine compounds for the treatment of cancer |
US9428509B2 (en) * | 2013-01-16 | 2016-08-30 | Signal Pharmaceuticals, Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
US20170137426A1 (en) * | 2014-03-28 | 2017-05-18 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as axl inhibitors |
EA201790189A1 (en) * | 2014-07-14 | 2017-11-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | METHODS OF TREATING MALIGNANT NUMER FORMATION USING SUBSTITUTED PYRROPYRYMIDIN COMPOUNDS, COMPOSITIONS ON THEIR BASIS |
CN105646496B (en) * | 2016-01-20 | 2018-07-20 | 华侨大学 | A kind of 7H- pyrrolo-es [2,3-d] pyrimidine derivatives, its synthetic method and application |
-
2018
- 2018-12-26 SG SG11202005983TA patent/SG11202005983TA/en unknown
- 2018-12-26 JP JP2020555729A patent/JP2021510729A/en active Pending
- 2018-12-26 AU AU2018397483A patent/AU2018397483A1/en not_active Abandoned
- 2018-12-26 EP EP18894176.9A patent/EP3731845A4/en not_active Withdrawn
- 2018-12-26 CA CA3086714A patent/CA3086714A1/en active Pending
- 2018-12-26 CN CN201880090513.2A patent/CN112203659A/en not_active Withdrawn
- 2018-12-26 WO PCT/US2018/067532 patent/WO2019133629A1/en unknown
- 2018-12-26 KR KR1020207020874A patent/KR20200104336A/en unknown
- 2018-12-26 US US16/958,721 patent/US11407757B2/en active Active
- 2018-12-28 TW TW107147559A patent/TWI691500B/en active
Also Published As
Publication number | Publication date |
---|---|
US20210009597A1 (en) | 2021-01-14 |
EP3731845A1 (en) | 2020-11-04 |
CN112203659A (en) | 2021-01-08 |
WO2019133629A8 (en) | 2020-01-16 |
AU2018397483A1 (en) | 2020-08-13 |
WO2019133629A1 (en) | 2019-07-04 |
TWI691500B (en) | 2020-04-21 |
EP3731845A4 (en) | 2021-10-06 |
JP2021510729A (en) | 2021-04-30 |
US11407757B2 (en) | 2022-08-09 |
KR20200104336A (en) | 2020-09-03 |
CA3086714A1 (en) | 2019-07-04 |
TW201930306A (en) | 2019-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL291000A (en) | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer | |
MX2017006366A (en) | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors. | |
PH12017501925A1 (en) | Pyrazole compounds and method for making and using the compounds | |
EP3310339A4 (en) | Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof | |
EP3672973A4 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
CL2016002382A1 (en) | Quinoxaline derivatives useful as modulators of fgfr kinase | |
IL282801A (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
WO2017108723A3 (en) | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | |
IL260263A (en) | Use of tryptophan derivatives for protein formulations | |
PH12015502041B1 (en) | Heteroaryl compounds and uses thereof | |
EA201591420A1 (en) | Heteroaryl Compounds and Their Use | |
EP3310776A4 (en) | Inhibitors of bruton's tyrosine kinase | |
MX2016015565A (en) | Certain protein kinase inhibitors. | |
IL250447A0 (en) | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof | |
EA201790395A1 (en) | AMINOTRIAZIN DERIVATIVES SUITABLE FOR USING AS TANK-BINDING KINASE INHIBITORS | |
EP3174539A4 (en) | Inhibitors of bruton's tyrosine kinase | |
IL259863B (en) | Polycyclic compounds as inhibitors of bruton's tyrosine kinase | |
EP3448852A4 (en) | Novel heterocyclic compounds as tyrosine kinase bcr-abl inhibitors | |
MX2018005987A (en) | Heterocyclic compounds for the treatment of disease. | |
EP3603638A4 (en) | COMBINATION THERAPY TECHNIQUE FOR Axl INHIBITORY AGENT AND EGFR TYROSINE KINASE INHIBITOR | |
SG11202005983TA (en) | Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors | |
ZA201908372B (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
GB2579149B (en) | Pharmaceutical composition for preventing or treating cancer containing receptor tyrosine kinase inhibitor as active ingredient | |
WO2014193696A3 (en) | Benzimidazole carboxylic acid derivatives, compositions, and methods of use as aurora kinase inhibitors | |
GB201705201D0 (en) | Novel compounds and their use as kinase inhibitors |